for Thank quarter joining you, thanks, Ira, conference and everyone, third our call.
and last SWK to Before He he praying family call. so the Adam, Adam family Rice, in we had on entire call. on you our night, that and be about a wanted start, on family is be was and the the I the today. CFO, acknowledge will for scheduled call the to death thinking not your speak
market product do to are a on innovative loans lien competitors as call. commercial first a investments. the segment SWK's million is and to core we believe royalties opportunities. stage underserved life our many million $X remains is on financing of science focused companies This Turning larger with $XX focus term business
and expertise and underwriting, and for the capabilities portfolio over documentation a We management. have this market of segment financed in have decade origination,
net During gross $XXX segment receivables quarter, increased finance portfolio non-GAAP The income. our adjusted to of the finance third year-over-year core million. generated $X XX%
points XX.X% the The yield with increased was as our $XX third quarter to year-over-year million XX revenue our The effective accompanied XX.X%, to yield. due an line to in to the average. yield loans. historical approximately Segment $X than realized by as year-over-year improved our XX.X% in grow -- receivables nonaccrual a less effective yield million realized increase portfolio basis
our we trend yield our effective in developments the yield. our positive bucket, historical exceeding of approximating expect or nonaccrual realized Given revert to should
third Relief. to and monetization During closed we up $X.XX the quarter, an $XX million advanced Therapeutics, have to royalty with million we Relief
the quarter, During million Eton's upsized support million year-end, is stated close also product. we by the Eton of disease deal a has to to will publicly rare to we Eton fund. a expected which at acquisition $XX time $XX a amendment closed Pharmaceuticals expect
value of Upon the XXX,XXX warrants signing dilutive the also our demonstrating the announced, SWK's value since $X.XX Eton solutions. price. minimally approximately of warrants a the was deal doubled amendment, of we Shares approximately strike Eton increasing have but at financing received
an to capital year-end, better. advancing discussing rated X multiple are existing loan to currently Medtech we or $X and closing we sponsor-backed now and Between a anticipate additional million borrowers CDMO, term
equity MOIC During to a XX% the third to and own loan full. IRR quarter, continue repaid in generated and our we The Epica. Epica X.X% was loan in a
$XX.X on of At finance X/XX, nonaccrual. million had we receivables
February $X.X sold On software SWK close, However, out to to we million XXXX. received its expects XX, close and million nonaccrual company. a post assets X Exeevo working $X.X November progress quarter cash made receive have in names. at
with January January payment owner contingent vendor. a is on X $XXX,XXX new X, receiving agreement anticipate also the executing XXXX, new existing this We -- approximately by although key an
X-year financials, consisting the a at in carrying XX. the accounting receive fourth the also to the the for this there SaaS quarter worked We XX% transaction SWK through our September increase as million but of value not $X.X of of gross will impairment an annual time, margin. in earn-out do is believe we
auction our to international Turning On held bidder to parties the timely won was with all-cash other close interested was believe and debtor to assets as an working not $XX.X estate. with time, will the transaction this the do the BIOLASE. million through XX, million. are fluid, of September BIOLASE for of work by November an SWK we X, orderly of an accounting and our But The an and the situation and purchase $XX.X third-party bid in fourth facilitate and impairment wind the for at the we of XXXX. value there's financials. down remains quarter attorneys carrying
to there September anticipate XX, believe not Turning in receiving proceeds of XXXX. repayment value facility to the of an We towards is months, loan. of the couple carrying next the $X.X the million as we do Trio impairment
against high, XXXX. our executing new segment support further things Fourth revenue is this should to are bookings which growth the with an out, round at plan revenue division all-time To quarter-to-date doubling Enteris quarter. $XXX,XXX business quarter in
inhaled with are is with it and making nasal our pleased progress as works a transition Phase and to strategic Enteris I We Phase CDMO. leading to partner the II
SWK our return book life quarter capital count, the portfolio commitments end based the Post to and growth per and and We our in drawn, term made In share progress XX% to on on tangible into diluted on will beyond. high. reduction combined and of forward. improve these with summary, an bucket, deploy value being close, and near unfunded science capital going expect believe we loans XXXX actions, we nonaccrual we considerable goal all-time share closings anticipated the continue with year near-term to achieve royalties attractive our our which positions in
questions. With that, let's to open call the